Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Nu.Q® Discover White Paper: The epigenetic keys to unlocking the full potential of immunotherapy

Tuesday, February 13, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: VolitionRx has released a new White Paper focusing on epigenetics and its implications for immunotherapy. The document highlights the importance of identifying markers that can predict treatment responses, which is crucial for enhancing patient outcomes in cancer therapies. This research underscores the growing significance of epigenetic insights in the field of medicine.
Price reaction · baseline $21.8 (2024-02-13T15:55:00.000Z) · hit during market hours · 4 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-4.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • The White Paper explores the potential of epigenetics in immunotherapy.
  • It aims to improve patient outcomes by predicting treatment responses.
  • The research could lead to significant advancements in cancer therapy.

Full Press Release Details

Our new White Paper is a deep dive into the science of epigenetics, and its potential to reveal deep insights into how our bodies react and respond to medication during cancer therapy and immunotherapies.
With the rise of novel immunotherapies, there is a need for markers that are able to predict treatment response or ineffectiveness, in order to improve patient outcomes.
Read the full White Paper here.

Related Articles

• Press Releases VolitionRx Announces Collaboration with Sysmex
• Press Releases VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

VolitionRx Announces Collaboration with Sysmex

VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is the focus of the new White Paper?

The White Paper focuses on epigenetics and its role in immunotherapy.

How can epigenetics improve cancer treatment?

Epigenetics can help identify markers that predict treatment responses, enhancing outcomes.

Who published the White Paper on epigenetics?

The White Paper was published by VolitionRx.

What is the significance of the research?

The research aims to unlock insights that could lead to better cancer therapies.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare VolitionRx Nu.Q® immunotherapy epigenetics cancer therapy
Last updated: Feb 13, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk